Historical record - last NADAC effective date: 1/4/2017
Product Information
DUETACT 30-4 MG TABLET is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $19.5115 per EA under NDC 64764030430. Its NADAC has been published 216 times since Nov 28, 2013.
FDA first approved this application on Jul 28, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4; 30 mg/1; mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
64764030430
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
1/4/2017
Active Ingredients
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA021925FDA Approved
7/28/2006
TE Code
AB
On Market Since
7/28/2006
Pharmacological Classes
Price Statistics
The NADAC for DUETACT 30-4 MG TABLET has been published 216 times since Nov 28, 2013, and over the history we have for it it has risen 65.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $19.5115 per EA |
|---|---|
| All-time high | $19.5115 (Jan 10, 2018) |
| All-time low | $11.8158 (Nov 28, 2013) |
| Median price | $17.2366 |
| Average price | $16.7690 |
| Largest weekly change | +9.9% (Jan 14, 2015) |
| Weeks tracked | 216 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+65.1%
Last surveyed Jan 10, 2018 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 46% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
pioglitazone and glimepiride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DUETACT 30-4 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DUETACT 30-4 MG TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $19.5115 per EA (NDC 64764030430), effective Jan 10, 2018.
How has the price of DUETACT 30-4 MG TABLET changed over time?
Over the history we have for it, the NADAC for DUETACT 30-4 MG TABLET has risen 65.1%. It has been tracked across 216 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DUETACT 30-4 MG TABLET?
Since Nov 28, 2013, the NADAC for DUETACT 30-4 MG TABLET has ranged from a low of $11.8158 (Nov 28, 2013) to a high of $19.5115 (Jan 10, 2018), with a median of $17.2366 per EA.
Are there cheaper alternatives to DUETACT 30-4 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PIOGLITAZONE-GLIMEPIRIDE 30-4, is $10.5176 per EA — about 46% below DUETACT 30-4 MG TABLET.
Who manufactures DUETACT 30-4 MG TABLET?
DUETACT 30-4 MG TABLET (NDC 64764030430) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.